From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar

Why It Matters

The convergence of MFN pricing, subsidy loss, and IRA reforms threatens drug affordability and the financial stability of community oncology providers, potentially shifting cancer care to higher‑cost hospital settings. This creates urgent policy stakes for legislators and payers ahead of the 2026 elections.

Key Takeaways

• MFN pricing covers 70% of targeted drug spending
• ACA subsidies expired, raising premiums 26% in 2026
• IRA Part B changes could cut oncology add‑on payments 49%
• Congressional action unlikely before midterms, limiting reforms
• Community oncology practices risk closures, shifting care to hospitals

Pulse Analysis

The push toward most‑favored‑nation drug pricing marks a strategic shift in U.S. health‑care cost control. By leveraging voluntary agreements with sixteen major manufacturers, the administration has secured price concessions that affect roughly 70 % of the drugs targeted under MFN. While this approach sidesteps lengthy rulemaking, it also raises questions about long‑term sustainability and the potential for market distortions if manufacturers resist future negotiations.

Simultaneously, the expiration of enhanced ACA marketplace subsidies has sent premiums soaring, with analysts projecting a 26 % average increase for 2026. The loss of subsidies threatens enrollment gains achieved in 2025, especially among low‑income consumers who now face steeper out‑of‑pocket costs. Insurers are scrambling to adjust risk pools, and policymakers confront a fiscal dilemma: restore subsidies at a $350 billion price tag or risk a wave of coverage gaps that could exacerbate health inequities.

Perhaps the most acute pressure point lies in the Inflation Reduction Act’s new Part B reimbursement methodology. By basing physician add‑on payments on a lower negotiated price, the IRA could reduce oncology add‑on revenues by nearly half, translating into $12‑$19 billion in losses through 2032. Community oncology clinics, already operating on thin margins, may be forced to close, pushing patients toward hospital‑based care that is costlier and less accessible. Stakeholders are urging a fix that mirrors the GLOBE and GUARD models, where the government compensates the price differential, preserving practice viability while still achieving drug‑price savings.